Simultaneous inhibition of PI3K (± mTOR) signalling with copanlisib (or BEZ235, respectively) was shown to effectively block osteoblast proliferation and prevent osteoblast-mediated resistance to TKIs in CML LSCs [89]. This evidence concerns the gene MTOR and chronic myelogenous leukemia, BCR-ABL1 positive.